S-Petasin 是一种磷酸二酯酶 (PDE) 抑制剂,对 PDE3 和 PDE4 的 IC50 值分别为 25.5 μM 和 17.5 μM,可抑制胆固醇侧链裂解酶、11β-羟化酶、PPAR-γ 以及 iNOS 在 RNA 和蛋白水平的诱导表达,可诱导 apoptosis、激活 caspases、切割 PARP、调控线粒体膜通透性,并调节 BCL2/BAX、p53、Bcl-XL、MMP-2、MMP-9、p21、CDK4 和 cyclin D1 的表达,可减少炎症细胞聚集、细胞因子和 IgE 水平并提升血清 IgG2a 水平,可舒张分离的致敏豚鼠气管肌且具有胃肠道解痉活性,可降低扁桃体炎严重程度和哮喘发作频率,可用于前列腺癌、肥胖症、黑色素瘤、过敏性哮喘、哮喘和腹膜炎的研究。
产品编号: MS-Y89111 CAS No.: 70238-51-6 分子式: C19H26O3S 分子量: 334.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

S-Petasin 是一种磷酸二酯酶 (PDE) 抑制剂,对 PDE3 和 PDE4 的 IC50 值分别为 25.5 μM 和 17.5 μM,可抑制胆固醇侧链裂解酶、11β-羟化酶、PPAR-γ 以及 iNOS 在 RNA 和蛋白水平的诱导表达,可诱导 apoptosis、激活 caspases、切割 PARP、调控线粒体膜通透性,并调节 BCL2/BAX、p53、Bcl-XL、MMP-2、MMP-9、p21、CDK4 和 cyclin D1 的表达,可减少炎症细胞聚集、细胞因子和 IgE 水平并提升血清 IgG2a 水平,可舒张分离的致敏豚鼠气管肌且具有胃肠道解痉活性,可降低扁桃体炎严重程度和哮喘发作频率,可用于前列腺癌、肥胖症、黑色素瘤、过敏性哮喘、哮喘和腹膜炎的研究。

生物实验数据

生物活性 S-Petasin is a phosphodiesterase (PDE) inhibitor with IC50 values of 25.5 μM and 17.5 μM for PDE3 and PDE4, respectively; it inhibits cholesterol side-chain cleavage enzyme, 11β-hydroxylase, PPAR-γ, and the induction of iNOS at both RNA and protein levels, induces apoptosis, activates caspases, cleaves PARP, regulates mitochondrial membrane permeability, and modulates the expression of BCL2/BAX, p53, Bcl-XL, MMP-2, MMP-9, p21, CDK4, and cyclin D1, reduces inflammatory cell infiltration, cytokine and IgE levels while elevating serum IgG2a levels, relaxes isolated sensitized guinea pig tracheal muscle and exhibits gastrointestinal antispasmodic activity, decreases the severity of tonsillitis and the frequency of asthma attacks, and can be used for research on prostate cancer, obesity, melanoma, allergic asthma, asthma, and peritonitis.
IC50 & Target

PDE3

25.5 μM (IC50)

PDE4

17.5 μM (IC50)

PDE3

25.3 μM (Ki)

PDE4

18.1 μM (Ki)

PPARγ

 

iNOS

 

体外研究
(In Vitro)

S-Petasin (10 nM-10 μM; 3-4 days) 呈剂量依赖性抑制 LNCaP、DU145 和 PC3 人前列腺癌细胞的增殖。
S-Petasin (0.1-10 μM; 12-18 h) 可激活胱天蛋白酶级联反应并诱导 LNCaP、DU145 和 PC3 人前列腺癌细胞中的 PARP 裂解,这与细胞凋亡的诱导一致。
S-Petasin (0.1-10 μM; 8-12 h) 可诱导人前列腺癌细胞 LNCaP、DU145 和 PC3 发生线粒体膜通透性破坏、细胞色素 c 释放,调控 BCL2 家族蛋白及 p53 的表达,从而触发线粒体介导的细胞凋亡。
S-petasin (0.31-1.55 μM; 8 days) 可剂量依赖性地抑制 3T3-L1 前脂肪细胞分化和葡萄糖摄取,在最高测试浓度下可将脂质积累量降至 30.18%。
S-petasin (0.31-1.55 μM; 8 days) 可剂量依赖性地抑制分化的 3T3-L1 脂肪细胞中甘油三酯的积累,在最高测试浓度下可将 TG 含量降至 61.04 %。
S-petasin (0.31-1.55 μM) 可剂量依赖性地抑制 3T3-L1 细胞中 PPAR-γ 的表达,且分化处理 8 天后的抑制作用强于处理 24 h 后的作用。
S-petasin (0.31-1.55 μM; 8 days) 可剂量依赖性地抑制分化的 3T3-L1 脂肪细胞中 PPAR-γ 靶基因 (HMGCR、FAS、CD36、Glut4、A-FABP、LPL) 的表达。
S-Petasin (2-160 μM; 24 h) 经 MTT 实验检测,在处理 24 h 后可强效抑制 B16F10 细胞 (IC50 = 42.16 μM) 和 A375 细胞 (IC50 = 36.90 μM) 的增殖。
S-Petasin (10-40 μM; 24 h) 经 Annexin V/PI 流式细胞术检测,在处理 24 h 后可呈浓度依赖性诱导 B16F10 细胞和 A375 细胞凋亡。
S-Petasin (10-40 μM; 24 h) 可通过下调促凋亡前体蛋白、上调 caspase 9、caspase 3 和 PARP-1 的活化剪切产物,在处理 24 h 后诱导 B16F10 细胞和 A375 细胞发生凋亡。
S-Petasin (10-40 μM; 24 h) 可通过降低细胞核内 NF-κB、MMP-2、MMP-9、Bcl-2、Bcl-xL、CDK4 及 cyclin D1 的表达,同时上调 Bax 和 p21 的表达,以浓度依赖的方式调控 B16F10 细胞和 A375 细胞中经 24 h 处理后的下游 p53 靶基因表达。
S-Petasin (4-40 μM; up to 24 h) 可通过划痕愈合实验检测到,其在 24 小时内以浓度依赖的方式抑制 B16F10 细胞和 A375 细胞的迁移。
S-Petasin (4-40 μM; 24 h) 经 24 h 处理后,以浓度依赖的方式抑制 B16F10 细胞和 A375 细胞通过 Max Gel ECM 的侵袭能力。
S-Petasin (10-40 μM; 24 h) 可在处理 24 h 后,以浓度依赖的方式在 B16F10 细胞和 A375 细胞中激活 p53 在 mRNA 和蛋白水平的表达。
S-Petasin (1-100 μM; 30 min) 可竞争性抑制豚鼠肺和心脏中的 PDE3 和 PDE4,对应的 IC50 值分别为 25.5 μM 和 17.5 μM;且在浓度高达 100 μM 时,不会抑制 PDE1、PDE2 或 PDE5。
S-Petasin 可强效抑制 RBL-2H3 肥大细胞中抗原诱导的脱颗粒作用,其 IC50 约为 1 nM。
S-Petasin (1-10 μM; 1 h preincubation, 24 h LPS stimulation) 可浓度依赖性地抑制 LPS 诱导的小鼠腹腔巨噬细胞 iNOS 蛋白和 mRNA 表达、NO 和 PGE2 生成。

Western Blot Analysis

Cell Line: LNCaP, DU145, PC3 (human prostate cancer cell lines)
Concentration: 0.1 μM, 1 μM, 10 μM
Incubation Time: 12, 18 h
Result: Reduced levels of procaspase 3, 7, 8, and 9 in LNCaP cells after 12 and 18 h.
Reduced levels of procaspase 3, 8, and 9 in DU145 cells after 12 and 18 h (procaspase 7 levels were unchanged).
Reduced levels of procaspase 3, 7, 8, and 9 in PC3 cells after 12 and 18 h.
Induced dose-dependent cleavage of PARP in all three cell lines after 12 and 18 h.

Western Blot Analysis

Cell Line: LNCaP, DU145, PC3 (human prostate cancer cell lines)
Concentration: 0.1 μM, 1 μM, 10 μM
Incubation Time: 8, 12 h
Result: Increased release of cytochrome c from mitochondria in LNCaP cells after 8 and 12 h.
Increased release of cytochrome c from mitochondria, downregulated BCL2, and downregulated p53 in PC3 cells after 8 and 12 h.
Increased release of cytochrome c from mitochondria, upregulated p53, upregulated BAX, downregulated BCL2, and induced BAX translocation in DU145 cells after 8 and 12 h.

Apoptosis Analysis

Cell Line: B16F10 murine melanoma cells, A375 human melanoma cells
Concentration: 10-40 μM
Incubation Time: 24 h
Result: Increased the proportion of Annexin V and PI positive cells in a concentration-dependent manner in both B16F10 and A375 cells.

Western Blot Analysis

Cell Line: B16F10 murine melanoma cells, A375 human melanoma cells
Concentration: 10 μM, 20 μM, 40 μM
Incubation Time: 24 h
Result: Decreased expression of pro-caspase 9, pro-caspase 3, and pro-PARP-1, while upregulated expression of cleaved-caspase 9, cleaved-caspase 3, and cleaved-PARP-1 in both B16F10 and A375 cells.\nDecreased nuclear NF-κB expression and suppressed MMP-2 and MMP-9 expression in a dose-dependent manner in both B16F10 and A375 cells.
Downregulated Bcl-2 and Bcl-xL expression, while upregulating Bax expression in a dose-dependent manner in both B16F10 and A375 cells.
Upregulated p21 expression, while suppressing CDK4 and cyclin D1 expression in a dose-dependent manner in both B16F10 and A375 cells.

Cell Migration Assay

Cell Line: B16F10 murine melanoma cells, A375 human melanoma cells
Concentration: 10 μM, 20 μM, 40 μM
Incubation Time: 24 h
Result: Reduced the number of migrated B16F10 and A375 cells in a dose-dependent manner, with statistically significant inhibition at all tested concentrations.

Cell Invasion Assay

Cell Line: B16F10 murine melanoma cells, A375 human melanoma cells
Concentration: 4 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 24 h
Result: Reduced the number of invaded B16F10 and A375 cells in a dose-dependent manner, with statistically significant inhibition at all tested concentrations.
体内研究
(In Vivo)

S-Petasin (10-30 μmol/kg (3.3-9.9 mg/kg); s.c.; 2 hours before, 6 and 24 hours after secondary OVA provocation) 可在过敏性哮喘小鼠模型中呈剂量依赖性地显著减轻气道高反应性、减少炎症细胞浸润、抑制促炎细胞因子的产生并调节免疫球蛋白水平。
S-Petasin (1 mg/kg; i.p.; 1 h before each ovalbumin nebulization) 可抑制卵清蛋白诱导的 BALB/c 小鼠支气管肺泡灌洗液中嗜酸性粒细胞、巨噬细胞和淋巴细胞的聚集,与未接受治疗的哮喘小鼠相比,其总细胞计数降低了 80%。
S-Petasin (1 mg/kg; i.p.; single dose 1 h prior to LPS injection) 可减少 LPS 诱导的 C57BL/6 小鼠腹腔总细胞、多形核白细胞及单核白细胞的聚集。

Animal Model: BALB/c (female, 8-12 weeks old, allergic asthma model via OVA sensitization and challenge)
Dosage: 10 μmol/kg; 30 μmol/kg
Administration: s.c.; 2 hours before, 6 and 24 hours after secondary OVA provocation
Result: Attenuated the enhanced pause (P_enh) value induced by 50 mg/mL methacholine in a dose-dependent and significant manner.
Suppressed increases in total inflammatory cells, neutrophils, and eosinophils in BALF in a significant manner.
Suppressed increases in lymphocytes in BALF at 30 μmol/kg dose, while 10 μmol/kg dose had no effect.
Left macrophage counts in BALF unchanged at both doses.
Suppressed increases in BALF levels of IL-2, IL-5, TNF-α, and IFN-γ in a significant manner at both doses.
Suppressed increases in BALF IL-4 levels at 30 μmol/kg dose, while 10 μmol/kg dose had no effect.
Reversed the reduction in serum total IgG2a levels in a significant manner at 30 μmol/kg dose.
Suppressed increases in serum total IgE, serum OVA-specific IgE, and BALF OVA-specific IgE in a dose-dependent and significant manner at both doses.
Suppressed increases in BALF total IgE levels at 30 μmol/kg dose, while 10 μmol/kg dose had no effect.
Animal Model: BALB/c (male, 6-week-old, adapted for 1 week prior to experimentation; asthma induced by intraperitoneal ovalbumin + alum on days 1 and 14, nebulized ovalbumin exposure on days 28-30)
Dosage: 1 mg/kg
Administration: i.p.; 1 h before each ovalbumin nebulization; 3 doses (days 28, 29, 30)
Result: Blunted ovalbumin-induced increase in total BALF cell number by approximately 80%.
Almost completely inhibited accumulation of macrophages and lymphocytes to PBS-treated basal levels.
Inhibited eosinophil accumulation by approximately 36%.
Animal Model: C57BL/6 (peritonitis induced by intraperitoneal 1 mg/kg LPS)
Dosage: 1 mg/kg
Administration: i.p.; single dose 1 h prior to LPS injection
Result: Reduced total peritoneal cell counts by 36% relative to LPS-induced controls.
Inhibited polymorphonuclear leukocyte accumulation by approximately 37%.
Inhibited mononuclear leukocyte accumulation by approximately 42%.
Did not significantly alter macrophage counts.

化学信息

分子量 334.47
分子式 C19H26O3S
CAS No. 70238-51-6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础